BEATS:针对时间至事件终点的贝叶斯混合设计及灵活样本量调整
本文提出BEATS贝叶斯混合设计,可基于外部数据异质性水平在设计期与期中分析阶段自适应借用外部数据以扩充对照组,并将BaSe-MAP先验扩展至时间至事件终点;期中分析可灵活调整样本量并开展无效性分析,最终分析整合校准后的外部数据量进行估计,以在控制同期对照规模的同时逼近等随机化比例的理想随机对照试验。
要点
- BEATS在设计期依据外部数据间异质性校准预期样本量与初始随机化比例。
- 期中分析可灵活调整样本量以处理同期对照与历史对照的冲突,并开展无效性分析。
- BEATS将BaSe-MAP扩展至时间至事件终点,以在冲突时获得较优把握度与稳健估计。
核心结论
- BEATS通过灵活样本量调整,在同期对照与外部数据出现冲突时提供较优把握度与稳健估计,并可在控制同期对照规模的同时逼近等随机化比例的理想随机对照试验。
研究设计与样本
- 方法学论文,提出贝叶斯混合设计BEATS,允许在设计期与期中分析阶段基于异质性水平自适应借用外部数据以扩充对照组。
主要发现
- BEATS将贝叶斯半参数Meta分析预测先验(BaSe-MAP)扩展至时间至事件终点,以实现最优借用表现。
- 设计期依据外部数据间异质性校准预期样本量与初始随机化比例。
- 期中分析进行灵活样本量调整以处理同期对照与历史对照的冲突,同时开展无效性分析。
- 最终分析整合校准后的外部数据量进行估计。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As the roles of historical trials and real-world evidence in drug development have substantially increased, several approaches have been proposed to leverage external data and improve the design of clinical trials. While most of these approaches focus on methodology development for borrowing information during the analysis stage, there is a risk of inadequate or absent enrollment of concurrent control due to misspecification of heterogeneity from external data, which can result in unreliable estimates of treatment effect. In this study, we introduce a Bayesian hybrid design with flexible sample size adaptation (BEATS) that allows for adaptive borrowing of external data based on the level of heterogeneity to augment the control arm during both the design and interim analysis stages. Moreover, BEATS extends the Bayesian semiparametric meta-analytic predictive prior (BaSe-MAP) to incorporate time-to-event endpoints, enabling optimal borrowing performance. Initially, BEATS calibrates the expected sample size and initial randomization ratio based on heterogeneity among the external data. During the interim analysis, flexible sample size adaptation is performed to address conflicts between the concurrent and historical control, while also conducting futility analysis. At the final analysis, estimation is provided by incorporating the calibrated amount of external data. Therefore, our proposed design allows for an approximation of an ideal randomized controlled trial with an equal randomization ratio while controlling the size of the concurrent control to benefit patients and accelerate drug development. BEATS also offers optimal power and robust estimation through flexible sample size adaptation when conflicts arise between the concurrent control and external data.
引用
- Bi D, Liu M, Lin J, et al. BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints. Stat Med. 2023. PMID: 37858287. doi:10.1002/sim.9936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。